The Resource Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt
Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt
Resource Information
The item Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Missouri University of Science & Technology Library.This item is available to borrow from 1 library branch.
Resource Information
The item Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Missouri University of Science & Technology Library.
This item is available to borrow from 1 library branch.
- Summary
- The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei
- Language
- eng
- Extent
- 1 online resource
- Contents
-
- pt. 1. Introduction
- pt. 2. The triple t paradigm : time, toxin, targeting
- pt. 3. Beyond the triple t-paradigm
- Isbn
- 9781299241954
- Label
- Fusion protein technologies for biopharmaceuticals : applications and challenges
- Title
- Fusion protein technologies for biopharmaceuticals
- Title remainder
- applications and challenges
- Statement of responsibility
- edited by Stefan R. Schmidt
- Subject
-
- Recombinant Fusion Proteins -- therapeutic use
- Biopharmaceutics
- Biopharmaceutics
- Drug Carriers
- Electronic books
- Electronic books
- Immunotoxins -- pharmacokinetics
- Immunotoxins -- therapeutic use
- MEDICAL -- Pharmacology
- Pharmaceutical biotechnology
- Pharmaceutical biotechnology
- Protein Engineering
- Recombinant Fusion Proteins -- pharmacokinetics
- Language
- eng
- Summary
- The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei
- Cataloging source
- DLC
- Dewey number
- 615.7
- Index
- index present
- LC call number
- RM301.4
- LC item number
- .F87 2013
- Literary form
- non fiction
- Nature of contents
-
- dictionaries
- bibliography
- NLM call number
- QU 450
- http://library.link/vocab/relatedWorkOrContributorName
- Schmidt, Stefan R
- http://library.link/vocab/subjectName
-
- Biopharmaceutics
- Pharmaceutical biotechnology
- Recombinant Fusion Proteins
- Drug Carriers
- Immunotoxins
- Immunotoxins
- Protein Engineering
- Recombinant Fusion Proteins
- MEDICAL
- Biopharmaceutics
- Pharmaceutical biotechnology
- Label
- Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt
- Bibliography note
- Includes bibliographical references and index
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
- pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm
- Control code
- 811850420
- Extent
- 1 online resource
- Form of item
- online
- Isbn
- 9781299241954
- Lccn
- 2012040270
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Specific material designation
- remote
- System control number
- (OCoLC)811850420
- Label
- Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt
- Bibliography note
- Includes bibliographical references and index
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
- pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm
- Control code
- 811850420
- Extent
- 1 online resource
- Form of item
- online
- Isbn
- 9781299241954
- Lccn
- 2012040270
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Specific material designation
- remote
- System control number
- (OCoLC)811850420
Subject
- Recombinant Fusion Proteins -- therapeutic use
- Biopharmaceutics
- Biopharmaceutics
- Drug Carriers
- Electronic books
- Electronic books
- Immunotoxins -- pharmacokinetics
- Immunotoxins -- therapeutic use
- MEDICAL -- Pharmacology
- Pharmaceutical biotechnology
- Pharmaceutical biotechnology
- Protein Engineering
- Recombinant Fusion Proteins -- pharmacokinetics
Genre
Member of
Library Links
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.library.mst.edu/portal/Fusion-protein-technologies-for/fHZUVl9C6CI/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.library.mst.edu/portal/Fusion-protein-technologies-for/fHZUVl9C6CI/">Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.library.mst.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.library.mst.edu/">Missouri University of Science & Technology Library</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Item Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.library.mst.edu/portal/Fusion-protein-technologies-for/fHZUVl9C6CI/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.library.mst.edu/portal/Fusion-protein-technologies-for/fHZUVl9C6CI/">Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.library.mst.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.library.mst.edu/">Missouri University of Science & Technology Library</a></span></span></span></span></div>
